Trials / Completed
CompletedNCT02443467
A Study to Determine the Safety and Tolerability of Herceptin as an Adjuvant Therapy of Early Breast Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 211 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This was an open-labeled, multi-center, prospective, non-comparative study of the safety of Herceptin (trastuzumab) used as an adjuvant therapy in patients with early breast cancer who had previously received antracycline therapy before or after surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No intervention |
Timeline
- Start date
- 2006-07-01
- Primary completion
- 2009-11-01
- Completion
- 2009-11-01
- First posted
- 2015-05-13
- Last updated
- 2016-11-02
Locations
1 site across 1 country: Serbia
Source: ClinicalTrials.gov record NCT02443467. Inclusion in this directory is not an endorsement.